Palo Alto, California 94304

  • Prostate Adenocarcinoma


This phase II/III trial studies how well gallium (Ga) 68-labeled gastrin-releasing peptide receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/magnetic resonance imaging (MRI) works in detecting prostate cancer in patients with negative computed tomography (CT) scan and elevated prostate-specific antigen levels after treatment with surgery or radiation. PET/MRI scans take both PET and MRI images at the same time and combine them into a single picture and is used to describe information regarding the function, as well as location and size of a tumor. 68Ga-RM2, a compound made of a radioactive agent linked to a pharmacological substance that is strongly attracted by a substance made by tumor cells, to detect prostate cancer. 68Ga-RM2 PET/MRI may be able to see smaller tumors than the standard of care contrast-enhanced CT or MRI scan

Study summary:

PRIMARY OBJECTIVES: I. To evaluate 68Ga-RM2 (formerly known as DOTA bombesin or BAY 86-7548) PET/MRI for detection of recurrent prostate cancer after initial therapy in patients with elevated prostate-specific antigen (PSA) and non-contributory computed tomography (CT). OUTLINE: Patients receive 68Ga-RM2 intravenously (IV) and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. After completion of study, patients are followed up at 24-48 hours and then at 1 year.


Inclusion Criteria: - Biopsy proven prostate adenocarcinoma - Rising PSA after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy - Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation - PSA greater than 0.2 ng/mL measured 6-13 weeks after RP - Confirmatory persistent PSA greater than 0.2 ng/mL - Post-radiation therapy - American Society for Therapeutic Radiology and Oncology (ASTRO)-Phoenix consensus definition - Nadir plus (+) greater than or equal to 2 ng/mL rise in PSA - No evidence of metastatic disease on conventional imaging, including a negative bone scan for skeletal metastasis and negative contrast-enhanced CT - Able to provide written consent - Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent) Exclusion Criteria: - Unable to provide informed consent - Inability to lie still for the entire imaging time - Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) - Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance - Metallic implants



Primary Contact:

Principal Investigator
Andrei Iagaru
Stanford University

Risa Jiron
Phone: 650-736-1598

Backup Contact:


Location Contact:

Palo Alto, California 94304
United States

Risa Jiron
Phone: 650-736-1598

Site Status: Recruiting

Data Source:

Date Processed: September 17, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.